Aurinia Pharmaceuticals' (AUPH) Voclosporin Phase 2b AURA-LV Study Meets Primary Endpoint in Lupus Nephritis
Tweet Send to a Friend
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
